1.77  -0.07 (-3.8%)		09-08 16:00
Open: 1.85 High: 1.89 Volume: 173,027		Pre. Close: 1.84 Low: 1.77 Market Cap: 5(M)

Short term
Mid term
Targets	6-month :	2.72	1-year :	3.31
Resists	First :	2.33	Second :	2.84
Pivot price	1.81
Supports	First :	1.5	Second :	1.25
MAs	MA(5) :	1.7	MA(20) :	1.96
	MA(100) :	2.89	MA(250) :	4.72
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	29.3	D(3) :	20.5
RSI	RSI(14): 41.5
52-week	High :	14.69	Low :	1.5

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ KAPA ] has closed above bottom band by 44.9%. Bollinger Bands are 12% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.89 - 1.9	1.9 - 1.91
Low:	1.75 - 1.76	1.76 - 1.77
Close:	1.75 - 1.77	1.77 - 1.79

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company focused on developing innovative treatments for individuals battling cancer. Its therapeutic portfolio includes a range of antibodies and small molecules engineered to combat various malignancies, such as prostate, lung, and breast cancer, as well as glioblastoma. Initially incorporated in 2013 under the name NanoGB13, Inc., the enterprise officially adopted its current identity as Kairos Pharma, Ltd. in July 2016. The company's operations are headquartered in Los Angeles, California.

Fri, 21 Aug 2026
Kairos Pharma Announces 1-for-7 Reverse Stock Split - Business Wire

Fri, 14 Aug 2026
Kairos Pharma (KAPA) Slides 5.3% to $0.34 as Micro-Cap Biotech Faces Pressure - Monthly Profile - vinanet.vn

Wed, 15 Jul 2026
CEO.CA's Inside the Boardroom: Kairos Pharma Might Change Cancer Treatment Forever - TradingView

Thu, 02 Jul 2026
Should I buy Kairos Pharma, Ltd. (KAPA) - Zacks Investment Research

Thu, 02 Jul 2026
All You Need to Know About Kairos Pharma, Ltd. (KAPA) Rating Upgrade to Buy - Yahoo Finance

Thu, 04 Jun 2026
New Kairos Pharma lung cancer drug targets $16.2B market - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.